An Australian blood plasma and vaccine giant under pressure over disappointing earnings and share price performance says not every decision it made was a bad one, as it pointed to a management shake-up.
Melbourne-based CSL, best known for its groundbreaking Gardasil cervical cancer vaccine, recently appointed a high-powered former GSK executive as its first female chief executive.
